XOMA Co. (NASDAQ:XOMA) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers boosted its stake in XOMA Co. (NASDAQ:XOMA) by 18.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 11,065 shares of the biotechnology company’s stock after acquiring an additional 1,699 shares during the quarter. Rhumbline Advisers’ holdings in XOMA were worth $291,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the last quarter. Barclays PLC raised its position in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the period. State Street Corp boosted its holdings in XOMA by 1.2% in the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after acquiring an additional 1,138 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Stock Up 0.6 %

Shares of XOMA stock opened at $21.82 on Monday. XOMA Co. has a twelve month low of $20.76 and a twelve month high of $35.00. The stock has a market cap of $257.11 million, a price-to-earnings ratio of -6.27 and a beta of 1.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The company has a fifty day moving average price of $25.41 and a 200 day moving average price of $27.69.

Insiders Place Their Bets

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

XOMA has been the topic of a number of research reports. StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a report on Tuesday, February 25th. HC Wainwright dropped their target price on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, February 3rd.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.